Feb 23, 2026
Novartis AG on the sale of its entire shareholding of Novartis India Limited (“NIL”)
AZB & Partners advised Novartis AG on the sale of its entire shareholding of Novartis India Limited (“NIL”), representing 70.68% of the equity share capital of NIL, to WaveRise Investments Limited, ChrysCapital Fund X and Two Infinity Partners (which form part of the ChrysCapital group).
Our deal team comprised our Senior Partner Darshika Kothari and Partner Kritika Agarwal, Counsel Arnav Shah, Associates Ashwin Vardarajan and Siddharth Tandon. They were supported on SEBI regulatory aspects by our Senior Consultant Harini Balaji, Partners Abhilash Chandran and Prerak Ved, Associates Akash Kumar Prasad and Hardik Batra; on the litigation aspects by our Senior Partner Rajendra Barot, Partner Prabhav Shroff and Senior Associate Ayush Chaddha; on the tax aspects by our Partner Aditya Singh Chandel, Senior Associates Suhail Bansal and Sarvagya Bilgaiyan; on the due diligence and other aspects by our Partners Nishanth Ravindran, Nandan Pendsey, Esq. and Avinash Subramanian, Senior Associates Shailesh Singh, Rhea Ghanshani, Riddhi Tulshian, Aditya Mukherjee, Harshit Jaiswal and Jay Shah, along with Associates Apurva Vats, Deepti Prabhu, Parvathy Suresh, Vivek Ilawat and Pratyush Chaturvedi; on the antitrust aspects by our Senior Partner Bharat Budholia and Partner Kirthi Srinivas, Senior Associate Varun Thakur and Associate Shivangi Pradhan.